aflatoxin b1 has been researched along with tamoxifen in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Kelly, MD; Park, BK; Tingle, MD; Wilson, AS | 1 |
| Ihara, T; Iida, N; Inoue, K; Myoubudani, H; Sugamata, M; Sugiyama, A; Tashiro, F; Ueno, Y | 1 |
| Ali-vehmas, T; Atroshi, F; Rizzo, A; Westermarck, T | 1 |
| Davies, R; Gant, TW; Smith, LL; Styles, JA | 1 |
| Hengstler, JG; Oesch, F; Steinberg, P; Van der Burg, B | 1 |
| Auriola, S; El-Nezami, H; Huuskonen, P; Kyllönen, T; Lehtonen, S; Pasanen, M; Storvik, M | 1 |
| LaForge, YS; Li, AP; Uzgare, A | 1 |
| Andrews, LS; Bachman, AN; Boogaard, PJ; Cadet, J; Embry, MR; Farmer, PB; Himmelstein, MW; Jarabek, AM; Kim, JH; Martin, EA; Mauthe, RJ; Persaud, R; Pottenger, LH; Preston, RJ; Schoeny, R; Skare, J; Swenberg, JA; Williams, GM; Zeiger, E; Zhang, F | 1 |
2 review(s) available for aflatoxin b1 and tamoxifen
| Article | Year |
|---|---|
Interspecies differences in cancer susceptibility and toxicity.
Topics: Aflatoxin B1; Animals; Antineoplastic Agents, Hormonal; Benzo(a)pyrene; Cardiotonic Agents; Cricetinae; Digitoxin; Disease Susceptibility; Endocrine System; Estrogens; Female; Heterocyclic Compounds; Humans; Male; Mice; Microsomes, Liver; Neoplasms; Polychlorinated Dibenzodioxins; Rabbits; Rats; Species Specificity; Tamoxifen | 1999 |
An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride.
Topics: Aflatoxin B1; Animals; Carcinogens; DNA Adducts; Dose-Response Relationship, Drug; Humans; Liver Neoplasms, Experimental; Mutagens; Mutation; Rats; Risk Assessment; Tamoxifen; Tissue Distribution; Vinyl Chloride | 2014 |
8 other study(ies) available for aflatoxin b1 and tamoxifen
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Evaluation of the generation of genotoxic and cytotoxic metabolites of benzo[a]pyrene, aflatoxin B1, naphthalene and tamoxifen using human liver microsomes and human lymphocytes.
Topics: 1-Propanol; Adult; Aflatoxin B1; Benzo(a)pyrene; Carcinogens; Cell Division; Environmental Pollutants; Epoxy Compounds; Estrogen Antagonists; Humans; Male; Microsomes, Liver; Mutagens; NADP; Naphthalenes; Propanols; Sister Chromatid Exchange; Spermatogenesis; Stilbenes; T-Lymphocytes; Tamoxifen; Trichloroepoxypropane | 1995 |
Suppression of arachidonic acid cascade-mediated apoptosis in aflatoxin B1-induced rat hepatoma cells by glucocorticoids.
Topics: Aflatoxin B1; Animals; Apoptosis; Arachidonic Acid; Carcinogens; Estradiol; Estrogen Antagonists; Gene Expression; Glucocorticoids; Lipoxygenase; Liver Neoplasms, Experimental; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Rats; Signal Transduction; Tamoxifen; Transforming Growth Factor beta | 1998 |
Effects of tamoxifen, melatonin, coenzyme Q10, and L-carnitine supplementation on bacterial growth in the presence of mycotoxins.
Topics: Aflatoxin B1; Antineoplastic Agents, Hormonal; Antioxidants; Bacteria; Carboxylic Acids; Carnitine; Cell Division; Coenzymes; Dose-Response Relationship, Drug; Erysipelothrix; Escherichia coli; Fumonisins; Lacticaseibacillus casei; Lactobacillus; Melatonin; Mycotoxins; Ochratoxins; Salmonella; Staphylococcus aureus; Streptococcus agalactiae; T-2 Toxin; Tamoxifen; Trichothecenes; Ubiquinone; Yersinia enterocolitica | 1998 |
Tamoxifen induces G:C-->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene.
Topics: Aflatoxin B1; Animals; Animals, Genetically Modified; Bacterial Proteins; CpG Islands; DNA Mutational Analysis; Dose-Response Relationship, Drug; Escherichia coli Proteins; Female; Genetic Vectors; Lac Repressors; Liver; Mutagenicity Tests; Point Mutation; Rats; Repressor Proteins; Tamoxifen; Transcription Factors; Transgenes; Viral Proteins | 1999 |
Aflatoxin B1--a potential endocrine disruptor--up-regulates CYP19A1 in JEG-3 cells.
Topics: Aflatoxin B1; Aflatoxins; Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Choriocarcinoma; Cytochrome P-450 CYP1A1; Drug Combinations; Endocrine Disruptors; Female; Gene Expression Regulation, Enzymologic; Humans; Nitriles; Poisons; Recombinant Proteins; Tamoxifen; Triazoles; Trophoblasts; Up-Regulation | 2011 |
Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclo
Topics: 3T3 Cells; Acetals; Aflatoxin B1; Animals; Coculture Techniques; Cyclophosphamide; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fibroblasts; Firefly Luciferin; Hepatocytes; Humans; Inactivation, Metabolic; Inhibitory Concentration 50; Mice; Tamoxifen; Toxicity Tests; Triazoles; Xenobiotics | 2012 |